Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 15/20 | 0.61 |
| ▸ | CA2 | P00918 | 15/20 | 0.61 |
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA9 | Q16790 | 3/20 | 0.61 |
| ▸ | KIF11 | P52732 | 2/20 | 0.55 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24732420 | 0.80 | CA1 (0.53) | CA1CA2FKBP1AGLAKMT2A | |
| SCHEMBL6352180 | 0.78 | CA1 (0.64) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL21033855 | 0.78 | CA1 (0.52) | CA1CA2FKBP1AGLAKMT2A | |
| SCHEMBL5684413 | 0.78 | CA1 (0.64) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL20490011 | 0.77 | KMT2A (0.54) | CA1CA2CA12CA9FKBP1A | |
| SCHEMBL20490050 | 0.77 | CA2 (0.53) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL14726352 | 0.76 | RAB9A (0.66) | CA1CA2CA12CA9CA4 | |
| SCHEMBL8519790 | 0.76 | CA1 (1.00) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL1615445 | 0.76 | ALDH1A1 (0.50) | CA1CA2FKBP1AGLAKMT2A | |
| SCHEMBL1645913 | 0.76 | CA1 (1.00) | CA1CA2CA12CA9KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4175630-A1 | POLYCYCLIC AMINES FOR OPIOID RECEPTOR MODULATION | Ecstasy LLC (US) | 2023-05-10 | — | — | EP | claimed |
| CN-117903016-A | Fluorosulfonyl sulfonimide salt, preparation method and application thereof | 中国科学院上海有机化学研究所 | 2024-04-19 | — | — | CN | disclosed |
| CN-113087687-A | Method for direct carbon-hydrogen alkynylation of thioamide-oriented aromatic hydrocarbon | 宁夏大学 | 2021-07-09 | — | — | CN | disclosed |
| CN-111100092-A | Method for direct amination of thioamide-oriented aromatic hydrocarbon carbon-hydrogen | 宁夏大学 | 2020-05-05 | — | — | CN | disclosed |
| CN-102816170-A | Novel macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE INC | 2012-12-12 | — | — | CN | disclosed |
| US-8299021-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299021-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | ARRAY BIOPHARMA, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | ARRAY BIOPHARMA, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2305696-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20090018166-A1 | New Pyridine Analogues X 161 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| CN-101263156-A | Novel macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE INC (US) | 2008-09-10 | — | — | CN | disclosed |
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| WO-2008085119-A1 | NEW PYRIDINE ANALOGUES VIII 518 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| EP-1924594-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2007015824-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015824-A2 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | CA1 4665/4885CA2 4474/4885CA12 4215/4885 |
| US-20090018166-A1 | New Pyridine Analogues X 161 | P2RY12, P2RY11, P2RY1 | CA1 4667/4885CA2 2852/4885CA12 4111/4885 |
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | P2RY12, P2RY13, P2RY11 | CA1 4124/4885CA2 1666/4885CA12 3505/4885 |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | CA1 4665/4885CA2 4474/4885CA12 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.